Jeroen Goos
Assistant Professor
E-mail: jeroen.goos@ki.se
Visiting address: BioClinicum J5:20, Akademiska Stråket 1, Universitetssjukhuset Solna, 17176 Stockholm
Postal address: K8 Klinisk neurovetenskap, K8 Neuro Holmin Goos, 171 77 Stockholm
Research
- The focus of my research group lies with the development of new tools for the
molecular imaging and treatment of patients with cancer. We use synthetic
molecules, but also biological compounds, that are labelled with radioactive
isotopes to specifically target the sites in the body where tumours are
located. Some of these isotopes can be detected using diagnostic imaging
devices (e.g. PET), whereas other isotopes are more suited for the delivery
of therapeutic doses of radioactivity that kill the tumour cells.
Our first research line aims at developing minimally invasive, nuclear
treatment strategies for patients that suffer from brain cancer. We are
using natural peptides and bispecific antibodies that are capable to
cross the blood-brain barrier (BBB) and then specifically bind to tumour
tissue.
In our second research line, we are developing new (radio)chemistry to
improve current pretargeting strategies. The pretargeting strategy
attempts to decrease radioactive doses to healthy tissues by injecting the
targeting vector (e.g. an antibody) and radioactive ligand separately, which
then ligate within the target tissue. By optimising the chemical and
physiological properties of both, the radioactive doses to healthy
tissues can significantly be reduced.
In our third research line, we use imaging isotopes to track immune cells in
the human body during immune cell therapy.
Articles
- Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108801
- Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108673
- Article: EJNMMI RESEARCH. 2023;13(1):73
- Article: MOLECULAR IMAGING AND BIOLOGY. 2021;23(6):952-962
- Article: POLYMER CHEMISTRY. 2020;11(35):5681-5692
- Journal article: MACROMOLECULAR RAPID COMMUNICATIONS. 2020;41(11)
- Article: MACROMOLECULAR RAPID COMMUNICATIONS. 2020;41(11):e2000061
- Article: NUCLEAR MEDICINE AND BIOLOGY. 2020;84-85:63-72
- Article: THERANOSTICS. 2020;10(2):567-584
- Article: JOURNAL OF NUCLEAR MEDICINE. 2019;60(11):1569-1578
- Article: BRITISH JOURNAL OF CANCER. 2016;115(12):1565-1574
- Journal article: CANCER RESEARCH. 2016;76(14_Supplement):3125
- Article: ONCOTARGET. 2016;7(2):2123-2134
- Article: NUCLEAR MEDICINE AND BIOLOGY. 2016;43(1):63-72
- Article: ANNALS OF SURGERY. 2016;263(1):138-145
- Article: ONCOTARGET. 2015;6(28):26278-26290
- Article: BRITISH JOURNAL OF CANCER. 2014;111(4):749-755
- Article: ONCOGENE. 2014;33(29):3861-3868
- Article: BRITISH JOURNAL OF CANCER. 2013;109(9):2445-2452
- Article: BRITISH JOURNAL OF CANCER. 2013;109(6):1636-1647
- Journal article: CANCER RESEARCH. 2013;73(8_Supplement):1151
- Article: MACROMOLECULAR RAPID COMMUNICATIONS. 2013;34(2):156-162
- Article: ZEITSCHRIFT FUR KRISTALLOGRAPHIE - CRYSTALLINE MATERIALS. 2012;227(11):739-743
- Article: AMERICAN JOURNAL OF SURGICAL PATHOLOGY. 2011;35(7):937-948
- Journal article: CANCER RESEARCH. 2011;71(8_Supplement):5217
- Article: SCIENCE. 2009;323(5920):1455-1458
- Show more
All other publications
- Corrigendum: MOLECULAR IMAGING AND BIOLOGY. 2022;24(3):510
- Book chapter: HANDBOOK OF RADIOPHARMACEUTICALS. 2020;p. 535-570
- Preprint: BIORXIV. 2020
- Review: FRONTIERS IN PHARMACOLOGY. 2018;9:831
- Conference publication: CANCER RESEARCH. 2015;:3419
- Conference publication: CANCER RESEARCH. 2014;:2853
- Conference publication: CANCER RESEARCH. 2014;:112
Grants
- Swedish Research Council1 January 2022 - 31 December 2025